NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (NASDAQ: NGEN), a clinical-stage […]
